187 related articles for article (PubMed ID: 37934581)
21. IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma.
Xu QG; Yu J; Guo XG; Hou GJ; Yuan SX; Yang Y; Yang Y; Liu H; Pan ZY; Yang F; Gu FM; Zhou WP
Mol Oncol; 2018 Jun; 12(6):936-952. PubMed ID: 29689643
[TBL] [Abstract][Full Text] [Related]
22. RING finger and WD repeat domain 3 regulates proliferation and metastasis through the Wnt/β-catenin signalling pathways in hepatocellular carcinoma.
Liang RP; Zhang XX; Zhao J; Lu QW; Zhu RT; Wang WJ; Li J; Bo K; Zhang CX; Sun YL
World J Gastroenterol; 2022 Jul; 28(27):3435-3454. PubMed ID: 36158256
[TBL] [Abstract][Full Text] [Related]
23. KIAA1429 mediates epithelial mesenchymal transition in sorafenib-resistant hepatocellular carcinoma through m6A methylation modification.
Kuang Y; Cheng Y; Wang J; Li H; Cao X; Wang Y
Cancer Med; 2023 Mar; 12(6):7222-7233. PubMed ID: 36420693
[TBL] [Abstract][Full Text] [Related]
24. [Trametenolic acid inhibits migration and invasion of hepatocellular carcinoma HepG2.2.15 cells via RhoC/ROCK1 pathway].
Wan YL; Wang JZ; Yuan Y; Ye WY; Li HL; Zhang XL; Zhang HQ; Li LE
Zhongguo Zhong Yao Za Zhi; 2024 Jan; 49(1):185-196. PubMed ID: 38403351
[TBL] [Abstract][Full Text] [Related]
25. RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-κB-mediated epithelial-mesenchymal transition.
Song FN; Duan M; Liu LZ; Wang ZC; Shi JY; Yang LX; Zhou J; Fan J; Gao Q; Wang XY
PLoS One; 2014; 9(9):e108507. PubMed ID: 25268581
[TBL] [Abstract][Full Text] [Related]
26. RARγ-induced E-cadherin downregulation promotes hepatocellular carcinoma invasion and metastasis.
Gan WJ; Wang JR; Zhu XL; He XS; Guo PD; Zhang S; Li XM; Li JM; Wu H
J Exp Clin Cancer Res; 2016 Oct; 35(1):164. PubMed ID: 27756432
[TBL] [Abstract][Full Text] [Related]
27. Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338-3p/RAB1B axis.
Xu C; Sun W; Liu J; Pu H; Li Y
Pathol Res Pract; 2023 May; 245():154435. PubMed ID: 37075641
[TBL] [Abstract][Full Text] [Related]
28. Furanocoumarin Notopterol: Inhibition of Hepatocellular Carcinogenesis through Suppression of Cancer Stemness Signaling and Induction of Oxidative Stress-Associated Cell Death.
Huang TY; Yang CK; Chen MY; Yadav VK; Fong IH; Yeh CT; Cherng YG
Nutrients; 2023 May; 15(11):. PubMed ID: 37299411
[TBL] [Abstract][Full Text] [Related]
29. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
30. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.
Yang C; Lu T; Liu M; Yuan X; Li D; Zhang J; Zhou L; Xu M
Phytomedicine; 2023 Mar; 111():154668. PubMed ID: 36657316
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
[TBL] [Abstract][Full Text] [Related]
32. Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
Makol A; Kaur H; Sharma S; Kanthaje S; Kaur R; Chakraborti A
Clin Mol Hepatol; 2020 Jan; 26(1):45-53. PubMed ID: 31564085
[TBL] [Abstract][Full Text] [Related]
33. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
34. Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27
Tang Y; Chen J; Li J; Zheng Y; Zhong X; Huang S; Chen B; Peng B; Zou X; Chen X
Phytomedicine; 2021 Jun; 86():153563. PubMed ID: 33951569
[TBL] [Abstract][Full Text] [Related]
35. Long non-coding RNA NRON is downregulated in HCC and suppresses tumour cell proliferation and metastasis.
Yao Z; Xiong Z; Li R; Liang H; Jia C; Deng M
Biomed Pharmacother; 2018 Aug; 104():102-109. PubMed ID: 29772429
[TBL] [Abstract][Full Text] [Related]
36. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway.
Wang J; Zhang N; Han Q; Lu W; Wang L; Yang D; Zheng M; Zhang Z; Liu H; Lee TH; Zhou XZ; Lu KP
Cancer Lett; 2019 Mar; 444():82-93. PubMed ID: 30583078
[TBL] [Abstract][Full Text] [Related]
37. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
[TBL] [Abstract][Full Text] [Related]
38. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
Feng J; Dai W; Mao Y; Wu L; Li J; Chen K; Yu Q; Kong R; Li S; Zhang J; Ji J; Wu J; Mo W; Xu X; Guo C
J Exp Clin Cancer Res; 2020 Jan; 39(1):24. PubMed ID: 32000827
[TBL] [Abstract][Full Text] [Related]
39. Polyphyllin I inhibits growth and invasion of cisplatin-resistant gastric cancer cells by partially inhibiting CIP2A/PP2A/Akt signaling axis.
Zhang Y; Huang P; Liu X; Xiang Y; Zhang T; Wu Y; Xu J; Sun Z; Zhen W; Zhang L; Si Y; Liu Y
J Pharmacol Sci; 2018 Jul; 137(3):305-312. PubMed ID: 30119963
[TBL] [Abstract][Full Text] [Related]
40. TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A.
Zhang Y; Tao R; Wu SS; Xu CC; Wang JL; Chen J; Yu YS; Tang ZH; Chen XH; Zang GQ
J Exp Clin Cancer Res; 2018 Jun; 37(1):116. PubMed ID: 29898761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
